Kidney Disease News and Research

RSS

Osprey Medical closes IPO raising of A$20 million

Osprey Medical Inc, has today announced that its Initial Public Offer (IPO) raising of A$20 million has closed. Osprey Medical’s Offer was well supported by institutional and retail investors in Australia, including founding investors CM Capital and Brandon Capital. The Initial Public Offer was underwritten by Shaw Corporate Finance.

17 Apr 2012

AstraZeneca introduces DUTOPROL for hypertension

AstraZeneca today announced the availability of DUTOPROL (metoprolol succinate extended release/hydrochlorothiazide) Tablets, the first and only once-daily antihypertensive agent that contains the active ingredient of TOPROL-XL (metoprolol succinate) plus a low-dose diuretic that provides proven blood pressure lowering at 24 hours.

12 Apr 2012

Enrollment complete for Ampio's multiple indication diagnostic clinical trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced today that it has completed enrollment of patients for its multiple indication diagnostic clinical trials.

12 Apr 2012

Amgen enters agreement to acquire KAI Pharmaceuticals

Amgen and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.

11 Apr 2012

DaVita introduces Kidney Smart website for patients with CKD

DaVita Inc., a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today announced the launch of its Kidney Smart website, for anyone with questions about CKD.

10 Apr 2012

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS (peginesatide) Injection.

10 Apr 2012

Three ESRD products chosen for FDA's Innovation Pathway program

Three products for patients with end stage renal disease (ESRD) have been chosen to participate in the FDA's Innovation Pathway, an evolving system designed to help medical devices reach patients in a safe, timely and collaborative manner.

10 Apr 2012

Aristolochic acid exposure leads to kidney failure and UUC

Aristolochic acid (AA), a component of a plant used in herbal remedies since ancient times, leads to kidney failure and upper urinary tract cancer (UUC) in individuals exposed to the toxin.

10 Apr 2012

Ampio submits pre-IND package on Zertane to FDA

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

9 Apr 2012

Poor mental health can lead to heart problems and death in dialysis patients

Dialysis patients whose mental health deteriorates over time have an increased risk of developing heart problems and dying prematurely, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

6 Apr 2012

Majority of female kidney failure patients on dialysis may experience sexual problems

The vast majority of female kidney failure patients on dialysis may experience sexual problems, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Additional studies are needed to understand how sexual dysfunction affects dialysis patients' quality of life and psychological wellbeing.

6 Apr 2012

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).

6 Apr 2012

Hypertensive dialysis patient survives 17 years on the waiting list for a new kidney

Jimmie Jones of Calumet Park, Ill., has beaten all odds to survive 17 years on the waiting list for a new kidney.

5 Apr 2012

Financial incentives for purchasing a healthier food option

The aging baby boomers and subsequent generations will be looking to the food industry to provide products that can help them live longer, healthier and more active lives than previous generations, according to research presented at the Institute of Food Technologists' Wellness 12 meeting.

5 Apr 2012

ASN participates in ABIM Foundation's Choosing Wisely campaign

The American Society of Nephrology (ASN), the world's leading kidney organization, joins the American Board of Internal Medicine (ABIM) Foundation, eight other leading national medical specialty societies, and Consumer Reports in the new Choosing Wisely campaign that helps health care professionals and patients avoid wasteful and sometimes harmful medical interventions.

5 Apr 2012

Bare platinum coils vs. newer gel-coated coils for aneurysm treatment

Approximately 6 million Americans have brain aneurysms, a condition that occurs when a weak or thin spot develops on a blood vessel in the brain causing it to balloon. Often, these do not cause symptoms and go undetected, but every year an estimated 30,000 Americans experience a ruptured aneurysm that bleeds into the brain causing a life threatening injury.

4 Apr 2012

Amgen, UCB commence CDP7851/AMG 785 Phase 3 trial in postmenopausal osteoporosis

UCB and Amgen announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

4 Apr 2012

AlloCure closes $25 million Series B venture financing

AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced the closing of a $25 million Series B venture financing.

2 Apr 2012

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it reached agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012.

2 Apr 2012